Search
Bronopol
go.drugbank.com/drugs/DB13960ApprovedThe agent is largely available commercially as an antibacterial for a variety of industrial purposes while it is predominantly available for purchase as a pet animal litter antibacterial at the domestic … First synthesized in 1897, bronopol was primarily used as a preservative for pharmaceuticals and was registered in the United States in 1984 for use in industrial bactericides, slimicides and preservatives
Categories: Compounds used in a research, industrial, or household settingNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigational), another tyrosine kinase inhibitor used as a first-line treatment for CML. … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML).
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexArimoclomol
go.drugbank.com/drugs/DB05025ApprovedArimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer. … [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
Echothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnUnfortunately, many patients experience a relapse or develop resistance to these drugs. … While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated
Cefepime
go.drugbank.com/drugs/DB01413ApprovedInvestigationalCefepime is a fourth-generation cephalosporin antibiotic developed in 1994. … [A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: CEFEPIME KABI POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1 g/vial, CEFEPIME KABI POWDER FOR SOLUTION FOR INJECTION OR INFUSION 2 g/vialMaftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection.
Categories: Treatments for Ebola Virus DiseaseCefmetazole
go.drugbank.com/drugs/DB00274ApprovedA semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. … It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. … It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332]
Choline C 11
go.drugbank.com/drugs/DB09277ApprovedCholine C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.